Raymond James & Associates Esperion Therapeutics, Inc. Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Esperion Therapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 50,657 shares of ESPR stock, worth $116,511. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,657
Previous 56,877 10.94%
Holding current value
$116,511
Previous $126,000 34.13%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
SELL
$1.61 - $2.73 $10,014 - $16,980
-6,220 Reduced 10.94%
50,657 $83,000
Q1 2024

Apr 22, 2024
BUY
$2.02 - $3.02 $35,404 - $52,931
17,527 Added 44.54%
56,877 $152,000
Q4 2023

Jan 16, 2024
BUY
$0.73 - $3.08 $12,874 - $54,318
17,636 Added 81.22%
39,350 $117,000
Q3 2023

Oct 24, 2023
BUY
$0.96 - $1.79 $4,394 - $8,194
4,578 Added 26.72%
21,714 $21,000
Q2 2023

Jul 25, 2023
BUY
$1.2 - $1.76 $3,357 - $4,924
2,798 Added 19.51%
17,136 $23,000
Q1 2023

Apr 14, 2023
SELL
$1.46 - $7.3 $34,441 - $172,207
-23,590 Reduced 62.2%
14,338 $22,000
Q4 2022

Feb 08, 2023
BUY
$5.09 - $8.5 $193,053 - $322,388
37,928 New
37,928 $236,000
Q2 2022

Aug 12, 2022
BUY
$4.77 - $6.67 $51,706 - $72,302
10,840 New
10,840 $69,000
Q2 2021

Aug 11, 2021
SELL
$19.4 - $28.71 $440,787 - $652,319
-22,721 Closed
0 $0
Q1 2021

May 14, 2021
BUY
$25.12 - $36.89 $280,364 - $411,729
11,161 Added 96.55%
22,721 $637,000
Q4 2020

Feb 12, 2021
BUY
$24.2 - $35.76 $64,541 - $95,371
2,667 Added 29.99%
11,560 $301,000
Q3 2020

Nov 04, 2020
BUY
$31.18 - $52.71 $122,475 - $207,044
3,928 Added 79.11%
8,893 $331,000
Q2 2020

Jul 28, 2020
BUY
$30.04 - $51.31 $149,148 - $254,754
4,965 New
4,965 $255,000
Q1 2020

Apr 21, 2020
SELL
$27.44 - $73.84 $109,074 - $293,514
-3,975 Closed
0 $0
Q4 2019

Feb 12, 2020
BUY
$35.4 - $59.82 $140,715 - $237,784
3,975 New
3,975 $237,000
Q3 2019

Nov 07, 2019
SELL
$34.47 - $47.53 $174,418 - $240,501
-5,060 Closed
0 $0
Q2 2019

Aug 06, 2019
BUY
$40.1 - $52.33 $202,906 - $264,789
5,060 New
5,060 $235,000
Q4 2018

Feb 11, 2019
SELL
$36.99 - $59.11 $247,796 - $395,977
-6,699 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$40.74 - $51.41 $272,917 - $344,395
6,699 New
6,699 $297,000
Q3 2017

Nov 13, 2017
SELL
$43.8 - $52.77 $227,759 - $274,404
-5,200 Closed
0 $0
Q2 2017

Aug 14, 2017
BUY
N/A
5,200
5,200 $241,000

Others Institutions Holding ESPR

# of Institutions
206
Shares Held
128M
Call Options Held
1.67M
Put Options Held
930K
View Full List

About Esperion Therapeutics, Inc.

ESPR Quotes by TradingView
  • Ticker ESPR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,551,600
  • Market Cap $153M
  • Description
  • Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascul...
More about ESPR
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email